Induction intra-arterial cisplatin and bleomycin in head and neck cancer

S. Frustaci, L. Barzan, G. Caruso, R. Ghirardo, S. Foladore, A. Carbone, R. Comoretto, I. Serafini, S. Monfardini

Research output: Contribution to journalArticlepeer-review


Fifty-two consecutive patients, affected by large T2 (>3 cm), T3, T4, N0, or N1 previously untreated squamous cell carcinoma of the head and neck, entered this phase I-II study. Treatment consisted of a continuous 8-day infusion on the following daily schedule: cisplatin 25 mg and bleomycin 15 mg administered for 4 and 20 hours, respectively. Technical-related toxicities were 1 case each of coagulation and displacement of the catheter and 1 case of reversible monoparesis of the contralateral arm. Drug-related relevant toxicities accounted for 4 cases of grade 3 or 4 leukopenia and 2 cases of peripheral palsy of the 7th and 12th cranial nerve, respectively. Forty-five of 50 evaluable patients obtained an objective response. In particular, 13 patients obtained a complete response, 22 a partial response ≥75%, and 10 a partial response ≥50%. Furthermore, 5 of 31 patients showed a complete pathologic disappearance of the tumor, whereas in 12 of 31 only a microscopic residue was found.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalHead and Neck
Issue number4
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Induction intra-arterial cisplatin and bleomycin in head and neck cancer'. Together they form a unique fingerprint.

Cite this